Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.82 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.82 |
| ▸ | GUCY1A1 | Q02108 | 14/20 | 0.57 |
| ▸ | GUCY1B1 | Q02153 | 14/20 | 0.57 |
| ▸ | PDE5A | O76074 | 4/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30507540 | 1.00 | ADORA3 (0.82) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL18496418 | 0.99 | ADORA3 (0.81) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| Dimethyl Sulfoxide SCHEMBL1931525 | 0.96 | ADORA3 (0.76) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL18212216 | 0.93 | ADORA3 (0.82) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| Riociguat SCHEMBL245457 | 0.90 | KCNH2 (1.00) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| Riociguat SCHEMBL29357210 | 0.90 | KCNH2 (1.00) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| Riociguat SCHEMBL29419573 | 0.90 | KCNH2 (1.00) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| Riociguat SCHEMBL29379983 | 0.90 | KCNH2 (1.00) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL5765138 | 0.90 | ADORA3 (0.73) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL12593410 | 0.90 | KCNH2 (0.86) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 197 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220211702-A1 | METHODS AND MATERIALS FOR GENDER-DEPENDENT TREATMENT OF CARDIOVASCULAR DYSFUNCTION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2022-07-07 | — | — | US | claimed |
| EP-3952992-A1 | METHODS AND MATERIALS FOR GENDER-DEPENDENT TREATMENT OF CARDIOVASCULAR DYSFUNCTION | Mayo Foundation for Medical Education and Research (US) | 2022-02-16 | — | — | EP | claimed |
| WO-2020210707-A1 | METHODS AND MATERIALS FOR GENDER-DEPENDENT TREATMENT OF CARDIOVASCULAR DYSFUNCTION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2020-10-15 | — | — | WO | claimed |
| EP-2958914-B1 | FORMS OF METHYL {4,6-DIAMINO-2-[1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDINO-3-YL]PYRIMIDINO-5-YL}METHYL CARBAMATE | ADVERIO PHARMA GMBH (DE) | 2020-07-15 | — | — | EP | claimed |
| US-10568895-B2 | Methods and materials for treating calcific aortic valve stenosis | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2020-02-25 | — | — | US | claimed |
| US-10570130-B2 | Process for preparing methyl{4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamate and its purification for use as pharmaceutically active compound | ADVERIO PHARMA GMBH (DE) | 2020-02-25 | — | — | US | claimed |
| US-20190284186-A1 | PROCESS FOR PREPARING METHYL{4,6-DIAMINO-2-[1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3-YL]PYRIMIDIN-5-YL}METHYLCARBAMATE AND ITS PURIFICATION FOR USE AS PHARMACEUTICALLY ACTIVE COMPOUND | ADVERIO PHARMA GMBH (DE) | 2019-09-19 | — | — | US | claimed |
| EP-3291811-B1 | THE USE OF SGC STIMULATORS, SGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF DIGITAL ULCERS (DU) CONCOMITANT TO SYSTEMIC SCLEROSIS (SSC) | Bayer Pharma AG (DE) | 2019-08-07 | — | — | EP | claimed |
| US-10351562-B2 | Process for preparing methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-B]pyridin-3-yl]pyrimidin-5-yl}methylcarbamate and its purification for use as pharmaceutically active compound | ADVERIO PHARMA GMBH (DE) | 2019-07-16 | — | — | US | claimed |
| US-10238669-B2 | Methods and materials for treating calcific aortic valve stenosis | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2019-03-26 | — | — | US | claimed |
| WO-2011064156-A2 | METHOD FOR PRODUCING METHYL-{4,6-DIAMINO-2-[1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDINO-3-YL]PYRIMIDINO-5-YL} CARBAMATE AND ITS PURIFICATION FOR USE THEREOF AS PHARMACEUTICAL SUBSTANCE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-03 | — | — | WO | claimed |
| US-20110130411-A1 | PROCESS FOR PREPARING METHYL CARBAMATE AND ITS PURIFICATION FOR USE AS PHARMACEUTICALLY ACTIVE COMPOUND | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-02 | — | — | US | claimed |
| EP-2296661-A1 | SGC STIMULATORS, SGC ACTIVATORS AND COMBINATIONS THEREOF FOR THE TREATMENT OF HEARING IMPAIRMENT | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-03-23 | — | — | EP | claimed |
| US-20100210643-A1 | sGC STIMULATORS, sGC ACTIVATORS AND COMBINATIONS FOR THE TREATMENT OF UROLOGICAL DISORDERS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-19 | — | — | US | claimed |
| WO-2010081647-A2 | SGC STIMULATORS OF SGC ACTIVATORS IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-07-22 | — | — | WO | claimed |
| WO-2010049078-A1 | USE OF HELIUM-OXYGEN GAS MIXTURES FOR TREATING PULMONARY ARTERIAL HYPERTENSION | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-06 | — | — | WO | claimed |
| EP-2144605-A1 | sGC STIMULATORS, sGC ACTIVATORS AND COMBINATIONS FOR THE TREATMENT OF UROLOGICAL DISORDERS | Bayer HealthCare AG (DE) | 2010-01-20 | — | — | EP | claimed |
| WO-2009138165-A1 | SGC STIMULATORS, SGC ACTIVATORS AND COMBINATIONS THEREOF FOR THE TREATMENT OF HEARING IMPAIRMENT | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-11-19 | — | — | WO | claimed |
| WO-2008138483-A1 | sGC STIMULATORS, sGC ACTIVATORS AND COMBINATIONS FOR THE TREATMENT OF UROLOGICAL DISORDERS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-11-20 | — | — | WO | claimed |
| EP-1506193-B1 | CARBAMATE-SUBSTITUTED PYRAZOLOPYRIDINES | BAYER HEALTHCARE AG (DE) | 2006-06-21 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130411-A1 | PROCESS FOR PREPARING METHYL CARBAMATE AND ITS PURIFICATION FOR USE AS PHARMACEUTICALLY ACTIVE COMPOUND | AZI2, TPMT, KDM5B | ADORA3 2401/4885KCNH2 694/4885GUCY1A1 328/4885 |
| US-10351562-B2 | Process for preparing methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-B]pyridin-3-yl]pyrimidin-5-yl}methylcarbamate and its purification for use as pharmaceutically active compound | TPMT, AMD1, DPYD | ADORA3 1267/4885KCNH2 561/4885GUCY1A1 1683/4885 |
| US-10570130-B2 | Process for preparing methyl{4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamate and its purification for use as pharmaceutically active compound | TPMT, AMD1, DPYD | ADORA3 1267/4885KCNH2 561/4885GUCY1A1 1683/4885 |
| US-20100210643-A1 | sGC STIMULATORS, sGC ACTIVATORS AND COMBINATIONS FOR THE TREATMENT OF UROLOGICAL DISORDERS | PDE5A, PDE3B, PDE3A | ADORA3 2112/4885KCNH2 2632/4885GUCY1A1 16/4885 |
| US-20190284186-A1 | PROCESS FOR PREPARING METHYL{4,6-DIAMINO-2-[1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3-YL]PYRIMIDIN-5-YL}METHYLCARBAMATE AND ITS PURIFICATION FOR USE AS PHARMACEUTICALLY ACTIVE COMPOUND | TPMT, AMD1, DPYD | ADORA3 1267/4885KCNH2 561/4885GUCY1A1 1683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.